Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Rroji, Merita; Figurek, Andreja; Spasovski, Goce

doi:10.3390/toxins12030140

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?

Journal

Toxins

Date Issued

2020

Author(s)

Rroji, Merita

Figurek, Andreja

DOI

10.3390/toxins12030140

Abstract

Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis. The presence of chronic kidney disease-mineral and bone disorder (CKD-MBD) has shown a strong correlation with CV events and mortality. As a non-atheromatous process, it could be partially explained why standard CV disease-modifying drugs do not provide such an impact on CV mortality in CKD as observed in the general population. We summarize the potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers.

File(s)

Name

should we consider.pdf

Size

1.22 MB

Format

Adobe PDF

Checksum

(MD5):2dc906c70784cb832f8f54ab9b86119d